Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Urotensin II, urotensin-related peptide, and their receptor in aortic valve stenosis.

Khan K, Albanese I, Yu B, Shalal Y, Al-Kindi H, Alaws H, Tardif JC, Gourgas O, Cerutti M, Schwertani A.

J Thorac Cardiovasc Surg. 2019 Sep 26. pii: S0022-5223(19)32013-6. doi: 10.1016/j.jtcvs.2019.09.029. [Epub ahead of print]

PMID:
31679703
2.

A Notch more: Molecular players in bicuspid aortic valve disease.

Lee A, Wei S, Schwertani A.

J Mol Cell Cardiol. 2019 Sep;134:62-68. doi: 10.1016/j.yjmcc.2019.05.018. Epub 2019 May 28. Review.

PMID:
31150732
3.

The cytoprotective impact of yes-associated protein 1 after ischemia-reperfusion injury in AC16 human cardiomyocytes.

Khan K, Makhoul G, Yu B, Schwertani A, Cecere R.

Exp Biol Med (Maywood). 2019 Jul;244(10):802-812. doi: 10.1177/1535370219851243. Epub 2019 May 29. No abstract available.

PMID:
31142144
4.

Bioactive scaffolds in stem-cell-based therapies for cardiac repair: protocol for a meta-analysis of randomized controlled preclinical trials in animal myocardial infarction models.

Khan K, Gasbarrino K, Mahmoud I, Makhoul G, Yu B, Dufresne L, Daskalopoulou SS, Schwertani A, Cecere R.

Syst Rev. 2018 Dec 5;7(1):225. doi: 10.1186/s13643-018-0845-z.

5.

Mouse Mast Cell Protease 4 Deletion Protects Heart Function and Survival After Permanent Myocardial Infarction.

Houde M, Schwertani A, Touil H, Desbiens L, Sarrhini O, Lecomte R, Lepage M, Gagnon H, Takai S, Pejler G, Jacques D, Gobeil F Jr, Day R, D'Orléans-Juste P.

Front Pharmacol. 2018 Aug 31;9:868. doi: 10.3389/fphar.2018.00868. eCollection 2018.

6.

Lipoprotein(a) Induces Human Aortic Valve Interstitial Cell Calcification.

Yu B, Hafiane A, Thanassoulis G, Ott L, Filwood N, Cerruti M, Gourgas O, Shum-Tim D, Al Kindi H, de Varennes B, Alsheikh-Ali A, Genest J, Schwertani A.

JACC Basic Transl Sci. 2017 Aug 28;2(4):358-371. doi: 10.1016/j.jacbts.2017.03.015. eCollection 2017 Aug.

7.

Pathological significance of lipoprotein(a) in aortic valve stenosis.

Yu B, Khan K, Hamid Q, Mardini A, Siddique A, Aguilar-Gonzalez LP, Makhoul G, Alaws H, Genest J, Thanassoulis G, Cecere R, Schwertani A.

Atherosclerosis. 2018 May;272:168-174. doi: 10.1016/j.atherosclerosis.2018.03.025. Epub 2018 Mar 15.

PMID:
29614432
8.

HDLs and the pathogenesis of atherosclerosis.

Schwertani A, Choi HY, Genest J.

Curr Opin Cardiol. 2018 May;33(3):311-316. doi: 10.1097/HCO.0000000000000508. Review.

PMID:
29561322
9.

Atherosclerotic Calcification: Wnt Is the Hint.

Albanese I, Khan K, Barratt B, Al-Kindi H, Schwertani A.

J Am Heart Assoc. 2018 Feb 8;7(4). pii: e007356. doi: 10.1161/JAHA.117.007356. No abstract available.

10.

Expression of the Frizzled receptors and their co-receptors in calcified human aortic valves.

Siddique A, Yu B, Khan K, Buyting R, Al-Kindi H, Alaws H, Rhéaume E, Tardif JC, Cecere R, Schwertani A.

Can J Physiol Pharmacol. 2018 Feb;96(2):208-214. doi: 10.1139/cjpp-2017-0577. Epub 2017 Dec 15.

PMID:
29244962
11.

Membrane microdomains and the regulation of HDL biogenesis.

Genest J, Schwertani A, Choi HY.

Curr Opin Lipidol. 2018 Feb;29(1):36-41. doi: 10.1097/MOL.0000000000000470. Review.

PMID:
29135688
12.

Desmocollin 1 is abundantly expressed in atherosclerosis and impairs high-density lipoprotein biogenesis.

Choi HY, Ruel I, Malina A, Garrod DR, Oda MN, Pelletier J, Schwertani A, Genest J.

Eur Heart J. 2018 Apr 7;39(14):1194-1202. doi: 10.1093/eurheartj/ehx340.

PMID:
29106519
13.

High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management.

Choi HY, Hafiane A, Schwertani A, Genest J.

Can J Cardiol. 2017 Mar;33(3):325-333. doi: 10.1016/j.cjca.2016.09.012. Epub 2016 Oct 20. Review.

PMID:
28063740
14.

Role of Noncanonical Wnt Signaling Pathway in Human Aortic Valve Calcification.

Albanese I, Yu B, Al-Kindi H, Barratt B, Ott L, Al-Refai M, de Varennes B, Shum-Tim D, Cerruti M, Gourgas O, Rhéaume E, Tardif JC, Schwertani A.

Arterioscler Thromb Vasc Biol. 2017 Mar;37(3):543-552. doi: 10.1161/ATVBAHA.116.308394. Epub 2016 Dec 8.

PMID:
27932350
15.

Correction: Deficiency of Interleukin-15 Confers Resistance to Obesity by Diminishing Inflammation and Enhancing the Thermogenic Function of Adipose Tissues.

Lacraz G, Rakotoarivelo V, Labbé SM, Vernier M, Noll C, Mayhue M, Stankova J, Schwertani A, Grenier G, Carpentier A, Richard D, Ferbeyre G, Fradette J, Rola-Pleszczynski M, Menendez A, Langlois MF, Ilangumaran S, Ramanathan S.

PLoS One. 2016 Nov 8;11(11):e0166537. doi: 10.1371/journal.pone.0166537. eCollection 2016.

16.

Deficiency of Interleukin-15 Confers Resistance to Obesity by Diminishing Inflammation and Enhancing the Thermogenic Function of Adipose Tissues.

Lacraz G, Rakotoarivelo V, Labbé SM, Vernier M, Noll C, Mayhue M, Stankova J, Schwertani A, Grenier G, Carpentier A, Richard D, Ferbeyre G, Fradette J, Rola-Pleszczynski M, Menendez A, Langlois MF, Ilangumaran S, Ramanathan S.

PLoS One. 2016 Sep 29;11(9):e0162995. doi: 10.1371/journal.pone.0162995. eCollection 2016. Erratum in: PLoS One. 2016 Nov 8;11(11):e0166537.

17.

Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2.

Goldberg AA, Joung KB, Mansuri A, Kang Y, Echavarria R, Nikolajev L, Sun Y, Yu JJ, Laporte SA, Schwertani A, Kristof AS.

Oncotarget. 2016 Sep 20;7(38):61152-61165. doi: 10.18632/oncotarget.10748.

18.

The Urotensin II System and Carotid Atherosclerosis: A Role in Vascular Calcification.

Albanese I, Daskalopoulou SS, Yu B, You Z, Genest J, Alsheikh-Ali A, Schwertani AG.

Front Pharmacol. 2016 Jun 7;7:149. doi: 10.3389/fphar.2016.00149. eCollection 2016.

19.

Conditioned medium of H9c2 triggers VEGF dependent angiogenesis by activation of p38/pSTAT3 pathways in placenta derived stem cells for cardiac repair.

Makhoul G, Jurakhan R, Jaiswal PK, Ridwan K, Li L, Selvasandran K, Duong M, Schwertani A, Cecere R.

Life Sci. 2016 May 15;153:213-21. doi: 10.1016/j.lfs.2016.04.009. Epub 2016 Apr 16.

PMID:
27091377
20.

Endothelin receptor antagonist macitentan or deletion of mouse mast cell protease 4 delays lesion development in atherosclerotic mice.

Houde M, Desbiens L, Schwertani A, Pejler G, Iglarz M, D'Orléans-Juste P.

Life Sci. 2016 Aug 15;159:71-75. doi: 10.1016/j.lfs.2016.03.018. Epub 2016 Mar 12.

PMID:
26976326
21.

Chymase inhibitor-sensitive synthesis of endothelin-1 (1-31) by recombinant mouse mast cell protease 4 and human chymase.

Semaan W, Desbiens L, Houde M, Labonté J, Gagnon H, Yamamoto D, Takai S, Laidlaw T, Bkaily G, Schwertani A, Pejler G, Levesque C, Desjardins R, Day R, D'Orléans-Juste P.

Biochem Pharmacol. 2015 Mar 15;94(2):91-100. doi: 10.1016/j.bcp.2015.02.001. Epub 2015 Feb 7.

PMID:
25667044
22.

International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function.

Vaudry H, Leprince J, Chatenet D, Fournier A, Lambert DG, Le Mével JC, Ohlstein EH, Schwertani A, Tostivint H, Vaudry D.

Pharmacol Rev. 2015;67(1):214-58. doi: 10.1124/pr.114.009480. Review.

PMID:
25535277
23.

Sustained release of milrinone delivered via microparticles in a rodent model of myocardial infarction.

Al Kindi H, Paul A, You Z, Nepotchatykh O, Schwertani A, Prakash S, Shum-Tim D.

J Thorac Cardiovasc Surg. 2014 Nov;148(5):2316-23. doi: 10.1016/j.jtcvs.2014.07.033. Epub 2014 Jul 31.

24.

Whole blood transcriptomics and urinary metabolomics to define adaptive biochemical pathways of high-intensity exercise in 50-60 year old masters athletes.

Mukherjee K, Edgett BA, Burrows HW, Castro C, Griffin JL, Schwertani AG, Gurd BJ, Funk CD.

PLoS One. 2014 Mar 18;9(3):e92031. doi: 10.1371/journal.pone.0092031. eCollection 2014.

25.

Circulating levels of the vasoactive peptide urotensin II in patients with acute coronary syndrome and stable coronary artery disease.

Al Kindi H, Hafiane A, You Z, Albanese I, Pilote L, Genest J, Schwertani A.

Peptides. 2014 May;55:151-7. doi: 10.1016/j.peptides.2014.03.004. Epub 2014 Mar 16.

PMID:
24642358
26.

Blocking the urotensin II receptor pathway ameliorates the metabolic syndrome and improves cardiac function in obese mice.

You Z, Al Kindi H, Abdul-Karim A, Barrette PO, Schwertani A.

FASEB J. 2014 Mar;28(3):1210-20. doi: 10.1096/fj.13-236471. Epub 2013 Dec 2.

PMID:
24297699
27.

A closer look at the role of urotensin II in the metabolic syndrome.

Barrette PO, Schwertani AG.

Front Endocrinol (Lausanne). 2012 Dec 28;3:165. doi: 10.3389/fendo.2012.00165. eCollection 2012.

28.

Genetic and pharmacological manipulation of urotensin II ameliorate the metabolic and atherosclerosis sequalae in mice.

You Z, Genest J Jr, Barrette PO, Hafiane A, Behm DJ, D'Orleans-Juste P, Schwertani AG.

Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1809-16. doi: 10.1161/ATVBAHA.112.252973. Epub 2012 Jun 21.

PMID:
22723440

Supplemental Content

Loading ...
Support Center